Complement Inhibitors as DMOADs

作为 DMOAD 的补体抑制剂

基本信息

  • 批准号:
    8730337
  • 负责人:
  • 金额:
    $ 7.88万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-08-15 至 2015-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Complement system play a role in preventing inflammation and joint immobility. Osteoarthritis (OA), an inflammatory disease of the joints, is quite prevalent among the elderly and causes disability in nearly 10% of the population over 55 years. Current medications only manage the disease and do not cure or halt the disease. The prevalence of OA coupled with the absence of Disease Modifying Osteoarthritis Drugs (DMOADs) heightens the negative impact of this disease on humanity. Recent studies have shown that cytokines are important in the development and progression of OA. It has been hypothesized that neutralizing IL-12 or TNF-1 may provide benefit to OA patients, hence, biologics or drugs that neutralize these cytokines are being investigated. Clinical trials with an anti-TNF-1 antibody are currently ongoing. The alternative pathway (AP) of complement has recently been implicated in the etiology of OA. We have developed a proprietary group of antibodies that selectively target the AP without affecting the host defense mediated via the classical pathway (CP). Our preliminary results suggest that the AP plays an important role in the development and progression of OA and that our target antibody is highly effective in resolving OA as indicated by rabbit models of OA. The current application proposes development of a humanized IgG1 as a potent treatment for halting and arresting the progression of OA in humans. In the Phase I segment, we further test a specific neutralizing anti-complement monoclonal antibody in the young rabbit OA model. In the Phase II segment, we will study the efficacy of the targeted humanized antibody to aged rabbits, evaluate the efficacy of the biologic in multiple modes of administration, and establish protocol for scaled up preparation of the humanized antibody. Our studies will provide new insight into the development of novel therapies for the treatment of OA. Overall, the proposed work is a critical step in the direction of developing a cost-effective, efficacious and safe therapeutic agent for preventing joint damage caused by OA.
描述(申请人提供):补体系统在预防炎症和关节不活动方面发挥作用。骨关节炎 (OA) 是一种关节炎症性疾病,在老年人中相当普遍,导致 55 岁以上人口中近 10% 致残。目前的药物只能控制疾病,不能治愈或阻止疾病。 OA 的流行加上疾病修饰骨关节炎药物 (DMOAD) 的缺乏加剧了这种疾病对人类的负面影响。 最近的研究表明细胞因子在 OA 的发生和进展中很重要。据推测,中和 IL-12 或 TNF-1 可能会给 OA 患者带来益处,因此,正在研究中和这些细胞因子的生物制剂或药物。目前正在进行抗 TNF-1 抗体的临床试验。最近,补体替代途径 (AP) 与 OA 的病因学有关。我们开发了一组专有的抗体,可以选择性地靶向 AP,而不影响通过经典途径 (CP) 介导的宿主防御。我们的初步结果表明,AP 在 OA 的发生和进展中发挥着重要作用,并且我们的目标抗体在解决 OA 方面非常有效,如兔 OA 模型所示。 目前的申请建议开发人源化 IgG1 作为阻止和阻止人类 OA 进展的有效治疗方法。在第一阶段阶段,我们进一步在幼兔 OA 模型中测试特异性中和抗补体单克隆抗体。在II期阶段,我们将研究靶向人源化抗体对老年兔的功效,评估生物制剂在多种给药模式下的功效,并建立人源化抗体的放大制备方案。我们的研究将为开发治疗 OA 的新疗法提供新的见解。总的来说,这项工作是开发一种具有成本效益、有效且安全的治疗剂来预防 OA 引起的关节损伤的关键一步。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Rekha Bansal其他文献

Rekha Bansal的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Rekha Bansal', 18)}}的其他基金

Disease Modifying Treatment for Hemolytic Disorders
溶血性疾病的疾病修饰治疗
  • 批准号:
    10254750
  • 财政年份:
    2021
  • 资助金额:
    $ 7.88万
  • 项目类别:
Treatment of Complement-Mediated Myelitis
补体介导的脊髓炎的治疗
  • 批准号:
    10254752
  • 财政年份:
    2021
  • 资助金额:
    $ 7.88万
  • 项目类别:
Single Therapy for Wet AMD & Geographic Atrophy
湿性 AMD 的单一疗法
  • 批准号:
    8781709
  • 财政年份:
    2014
  • 资助金额:
    $ 7.88万
  • 项目类别:
Preclinical and Clinical Evaluation of Humanized NM9405
人源化NM9405的临床前和临床评价
  • 批准号:
    8647587
  • 财政年份:
    2014
  • 资助金额:
    $ 7.88万
  • 项目类别:
Preclinical and Clinical Evaluation of Humanized NM9405
人源化NM9405的临床前和临床评价
  • 批准号:
    8925257
  • 财政年份:
    2014
  • 资助金额:
    $ 7.88万
  • 项目类别:
Preclinical and Clinical Evaluation of Humanized NM9405
人源化NM9405的临床前和临床评价
  • 批准号:
    9038429
  • 财政年份:
    2014
  • 资助金额:
    $ 7.88万
  • 项目类别:
Alternative Pathway Inhibitors for Orphan Indication
用于孤儿适应症的替代途径抑制剂
  • 批准号:
    8524040
  • 财政年份:
    2013
  • 资助金额:
    $ 7.88万
  • 项目类别:
Complement Inhibitors as DMOADs
作为 DMOAD 的补体抑制剂
  • 批准号:
    8701429
  • 财政年份:
    2013
  • 资助金额:
    $ 7.88万
  • 项目类别:
Alternative Pathway Inhibitors for Orphan Indication
用于孤儿适应症的替代途径抑制剂
  • 批准号:
    8883970
  • 财政年份:
    2013
  • 资助金额:
    $ 7.88万
  • 项目类别:
Complement Inhibitors as DMOADs
作为 DMOAD 的补体抑制剂
  • 批准号:
    8252300
  • 财政年份:
    2012
  • 资助金额:
    $ 7.88万
  • 项目类别:

相似海外基金

Exploring the mental health and wellbeing of adolescent parent families affected by HIV in South Africa
探讨南非受艾滋病毒影响的青少年父母家庭的心理健康和福祉
  • 批准号:
    ES/Y00860X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.88万
  • 项目类别:
    Fellowship
Scaling-up co-designed adolescent mental health interventions
扩大共同设计的青少年心理健康干预措施
  • 批准号:
    MR/Y020286/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.88万
  • 项目类别:
    Fellowship
Shared Spaces: The How, When, and Why of Adolescent Intergroup Interactions
共享空间:青少年群体间互动的方式、时间和原因
  • 批准号:
    ES/T014709/2
  • 财政年份:
    2024
  • 资助金额:
    $ 7.88万
  • 项目类别:
    Research Grant
Social Media Mechanisms Affecting Adolescent Mental Health (SoMe3)
影响青少年心理健康的社交媒体机制 (SoMe3)
  • 批准号:
    MR/X034925/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.88万
  • 项目类别:
    Fellowship
Parent-adolescent informant discrepancies: Predicting suicide risk and treatment outcomes
父母与青少年信息差异:预测自杀风险和治疗结果
  • 批准号:
    10751263
  • 财政年份:
    2024
  • 资助金额:
    $ 7.88万
  • 项目类别:
The Impact of Online Social Interactions on Adolescent Cognition
在线社交互动对青少年认知的影响
  • 批准号:
    DE240101039
  • 财政年份:
    2024
  • 资助金额:
    $ 7.88万
  • 项目类别:
    Discovery Early Career Researcher Award
Adolescent sugar overconsumption programs food choices via altered dopamine signalling
青少年糖过度消费通过改变多巴胺信号来影响食物选择
  • 批准号:
    BB/Y006496/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.88万
  • 项目类别:
    Research Grant
Resilience Factors, Pain, and Physical Activity in Adolescent Chronic Musculoskeletal Pain
青少年慢性肌肉骨骼疼痛的弹性因素、疼痛和体力活动
  • 批准号:
    10984668
  • 财政年份:
    2024
  • 资助金额:
    $ 7.88万
  • 项目类别:
Augmented Social Play (ASP): smartphone-enabled group psychotherapeutic interventions that boost adolescent mental health by supporting real-world connection and sense of belonging
增强社交游戏 (ASP):智能手机支持的团体心理治疗干预措施,通过支持现实世界的联系和归属感来促进青少年心理健康
  • 批准号:
    10077933
  • 财政年份:
    2023
  • 资助金额:
    $ 7.88万
  • 项目类别:
    EU-Funded
Family-Focused Adolescent & Lifelong Health Promotion (FLOURISH)
以家庭为中心的青少年
  • 批准号:
    10050850
  • 财政年份:
    2023
  • 资助金额:
    $ 7.88万
  • 项目类别:
    EU-Funded
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了